Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

FDA approves remote mobile communication device Dexcom SHARE

Dexcom, a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced that it has received US Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE.

Dexcom SHARE, an accessory to the Dexcom G4 PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers."

These followers can remotely monitor a patient’s glucose information and receive alert notifications from almost anywhere via their Apple® iPhone or iPod touch. With Dexcom SHARE, parents and personal caregivers can monitor a child’s or loved one’s glucose data from a remote location, giving them peace of mind and reassurance when they are apart.

"Dexcom SHARE represents a significant advance in diabetes care by allowing people with diabetes to share important glucose information with their loved ones from afar," said Terrance H. Gregg, Chief Executive Office of Dexcom. "With Dexcom SHARE, users, parents and personal caregivers now have a new tool to dramatically improve how they communicate about their diabetes."
The Dexcom SHARE consists of a small cradle device in which the Dexcom G4 PLATINUM is docked. The cradle also functions as a battery charger for the receiver and must be connected to an electrical outlet.

The Dexcom SHARE cradle is equipped with Bluetooth technology, enabling the device to wirelessly transmit glucose levels from the Dexcom G4 PLATINUM receiver to the Dexcom SHARE App on the patient’s Apple iPhone® or iPod touch.

The Dexcom SHARE App uploads glucose data to a secure server. Personal caregivers or parents can then remotely receive notifications about glucose levels and trends on their Apple® iPhone or iPod touch.

"Continuous glucose monitoring offers a unique opportunity for patients with diabetes to aim for glucose levels close to the reference range found in persons without diabetes," said Lori Laffel, M.D., M.P.H., Chief of the Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, in Boston, MA. "The ability to share the continuous glucose data remotely, to almost any location, is a remarkable advance. This new device should help patients, families and care providers succeed with their overall efforts to improve diabetes control and prevent both short-term and long-term complications while preserving quality of life for patients with diabetes and their family members."